The Federal Circuit reversed a $17.3M trade secret verdict and patent invalidity finding tied to a cosmetic medical implant, holding that information disclosed in publicly available patents is not protectable as a trade secret under California law.
The Federal Circuit reversed a district court ruling that had invalidated Teva's headache treatment patents under § 112, distinguishing the case from Amgen v. Sanofi by focusing on what the method-of-use claims actually cover.
In Fortress Iron v. Digger Specialties, the Federal Circuit held that when a co-inventor cannot be located and added under § 256(b), the patent is invalid.
In Hikma v. Amarin, SCOTUS will decide whether generic drug marketing statements can support induced infringement claims even when the FDA label carves out the patented use — with major implications f
